(Press-News.org) Contact information: Alan Gill
gill.a@wehi.edu.au
61-419-591-102
Walter and Eliza Hall Institute
More than skin deep: New layer to the body's fight against infection
The layers of skin that form the first line of defence in the body's fight against infection have revealed a unanticipated secret.
The single cell type that was thought to be behind the skin's immune defence has been found to have a doppelganger, with researchers from the Walter and Eliza Hall Institute showing the cells, despite appearing identical, are actually two different types.
Institute scientists Dr Michael Chopin, Dr Stephen Nutt and colleagues have been investigating Langerhans cells, the immune cells that provide the first line of defence against attacks through the skin.
Until recently, scientists believed that, because they looked identical, all Langerhans cells were also genetically identical and had the same function. However Dr Nutt said the research team, with collaborators from the National Institutes of Health, US, have shown this is not the case.
"Langerhans cells are produced and found in the skin and are quite unique among immune cells because they do not have a definite lifespan, they can last for a lifetime," Dr Nutt said. "They are only replaced when necessary, such as when the skin is damaged by a burn or a cut. When that happens, new Langerhans cells have to be produced by the bone marrow. These cells look the same, so it was always thought that they were genetically the same and their function was the same. We have shown that this isn't the case."
This surprise finding, published today in the Journal of Experimental Medicine, could have repercussions for developing and refining therapies for skin infections and skin cancers.
Although Langerhans cells were discovered nearly 150 years ago, Dr Chopin said there were still a lot of gaps in our knowledge about how they develop and their role in responding to foreign invaders. Dr Chopin said the research team was initially trying to understand the role of Langerhans cells. "Not everything that makes contact with the skin is harmful, so it is important the immune system doesn't overreact," he said. "We were trying to find out whether Langerhans cells were there to activate an immune response to invaders, or to suppress the immune system to prevent it from overreacting.
"While designing the experiment, we found that the genes that define the Langerhans cells that are produced in the skin were different to those of Langerhans cells that came from bone marrow. In essence we now know that there are two different types of Langerhans cells where we thought there was one. We now need to find out if they behave differently as well."
Dr Nutt said the research could explain why some promising new drugs have not had the desired effect in the clinic. "Some clinical trials of drugs that were designed to help boost Langerhans cells in response to infections have not responded as the researchers expected," Dr Nutt said. "Our finding may help explain why these drugs didn't work outside the laboratory and our current research may provide guidance in developing therapeutics to treat skin infections or skin cancer."
INFORMATION:
The research was funded by the Australian National Health and Medical Research Council and the Victorian Government.
More than skin deep: New layer to the body's fight against infection
2013-11-18
ELSE PRESS RELEASES FROM THIS DATE:
Bacteria use lethal cytotoxins to evade antibiotic treatment
2013-11-18
Bacteria use lethal cytotoxins to evade antibiotic treatment
In spite of the fact that the first antibiotics were discovered almost a century ago, infectious diseases such as tuberculosis, encephalitis and meningitis are still serious diseases for humans in the ...
Manipulation of protein could help stop spread of cancer cells
2013-11-18
Manipulation of protein could help stop spread of cancer cells
DNA regulator stops cancer cells in their tracks
Understanding how and why cancer cells move away from their original location is important to find ways to stop the spread of the disease. ...
Vismodegib in basal cell carcinoma: Added benefit not proven
2013-11-18
Vismodegib in basal cell carcinoma: Added benefit not proven
Hardly any patient-relevant outcomes were investigated/ studies without control groups
The drug vismodegib (trade name: Erivedge) is approved for the treatment of patients ...
Amber provides new insights into the evolution of the Earth's atmosphere
2013-11-18
Amber provides new insights into the evolution of the Earth's atmosphere
Scientists encounter big challenges when reconstructing atmospheric compositions in the Earth's geological past because of the lack of useable sample material. One of the few ...
Would an 'anti-ketamine' also treat depression?
2013-11-18
Would an 'anti-ketamine' also treat depression?
Yes, says a new study in Biological Psychiatry
Philadelphia, PA, November 18, 2013 – Thirteen years ago, an article in this journal first reported that the anesthetic medication, ketamine, showed evidence of producing ...
More than 600 ancient seals and amulets found
2013-11-18
More than 600 ancient seals and amulets found
Archaeologists from the Cluster of Excellence make an unusually large find in Turkey -- surprisingly vivid insights into the piety of the time
Classical scholars from the Cluster of Excellence "Religion ...
Nature: Single-atom bit forms smallest memory in the world
2013-11-18
Nature: Single-atom bit forms smallest memory in the world
This news release is available in German.
One atom equals one bit: According to this design principle, we would like to construct magnetic data memories in the future. Presently, a compound of several ...
First EU e-Inclusion map measures the potential for improved digital literacy
2013-11-18
First EU e-Inclusion map measures the potential for improved digital literacy
An EU-27 survey of intermediary organisations operating on the education, social and employment sectors and providing IT training has produced a first ever assessment ...
Cesarean delivery doesn't lower risk of cerebral palsy
2013-11-18
Cesarean delivery doesn't lower risk of cerebral palsy
Cesarean deliveries do not prevent children from developing cerebral palsy, despite long-held medical and community beliefs about the causes of cerebral palsy, according to new research ...
A study led by CNIO validates a new anti-cancer therapy based on cell division
2013-11-18
A study led by CNIO validates a new anti-cancer therapy based on cell division
The study confirms the therapeutic potential of inhibiting Aurora-A in cancer treatment
Aurora-A is a protein involved in the cell division process that is highly expressed ...